3 results

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer

Pedro Nazareth Aguiar Jr. ORCID logo , Pui San Tan ORCID logo , Sarah Simko ORCID logo , Carmelia Maria Noia Barreto ORCID logo , Bárbara de Souza Gutierres ORCID logo , Auro del Giglio ORCID logo , [...]

DOI: 10.31744/einstein_journal/2019GS4414

ABSTRACT Objective To evaluate the cost-effectiveness of the addition of chemotherapy or abiraterone to androgen deprivation. Methods We developed an analytical model to determine the cost-effectiveness of the addition of docetaxel or abiraterone versus androgen deprivation therapy alone. Direct and indirect costs were included in the model. The effects were expressed in Quality-Adjusted Life Years adjusted for side effects. Results Compared to androgen deprivation therapy alone, the addition of chemotherapy and of abiraterone generated 0.492 and 0.999, respectively, in Quality-Adjusted […]

Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer

Pedro Nazareth Aguiar Jr., Carmélia Maria Noia Barreto, Bárbara de Souza Gutierres, Hakaru Tadokoro, Gilberto de Lima Lopes Jr

DOI: 10.1590/S1679-45082017GS4017

ABSTRACT Objective To assess the cost-effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer. Methods An analytical decision model was developed to determine the cost-effectiveness of chemohormonal therapy versus androgen deprivation therapy alone in patients with metastatic hormone-sensitive prostate cancer and patients with non-metastatic high-risk prostate cancer. The cost-effectiveness in metastatic patients with a high-volume disease was assessed separately. The model used data from randomized clinical trials and drug acquisition costs in Brazil. In addition, […]

Efficacy and toxicity of mitoxantrone and oral etoposide in the treatment of hormone-refractory prostate cancer: pilot study

Rafael Kaliks, Camila Guerra, Auro Del Giglio

DOI: 10.1590/s1679-45082010ao1622

ABSTRACTObjective:To evaluate the efficacy and toxicity of the association of mitoxantrone and oral etoposide.Methods:Twelve consecutive patients with metastatic hormone-refractory prostate cancer were treated with mitoxantrone and oral etoposide. Toxicity, response rate and response duration were assessed.Results:Partial response was observed in two patients (response duration of seven and four months) and one patient had stable disease (during four months). Mitoxantrone and oral Etoposide were well tolerated and did not affect tolerability to subsequent chemotherapy.Conclusion:Mitoxantrone and oral etoposide association is an active […]